Trimtech Therapeutics
Trimtech Therapeutics develops a portfolio of protein degraders, specifically TRIMTACs and TRIMGLUEs, to selectively remove toxic protein aggregates. The company utilizes research into the TRIM21 ubiquitin ligase to address intractable central nervous system (CNS) and inflammatory disorders. Their therapeutic approach focuses on treating protein aggregation disorders through targeted protein degradation.
Visit websiteCambridge, UK
Biotechnology
Healthtech
Therapeutics
CNS
Inflammation
Funding summary
- Total raised
- €41.0M
- Funding rounds
- 2
Investors in Trimtech Therapeutics
Investors on record for Trimtech Therapeutics. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Trimtech Therapeutics?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors